Litigation
Nov. 25, 2015
Hepatitis C cure target of bad faith insurance claims
A class action filed Thursday on behalf of patients denied FDA-approved drug Harvoni is the latest outcry against Blue Cross and Blue Shield for allegedly requiring patients to reach stage IV sickness before deeming the cure medically necessary.
Daily Journal Staff Writer
A class action filed on behalf of patients denied insurance coverage for Harvoni, a cure for hepatitis C approved last year by the Food and Drug Administration, is one of a dozen suits brought against Blue Cross of California and Blue Shield of California this year for requiring policyholders to reach late-stage liver scarring before deeming the drug medically necessary.
Brought to market ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In